Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
$32.54
-1.3%
$29.40
$13.70
$34.14
$65.70B1.022.55 million shs3.21 million shs
The Flowr Co. stock logo
FLWR
Flowr
C$0.03
C$0.02
C$0.02
C$0.11
C$10.66MN/A302,866 shs29,006 shs
HEXO Corp. stock logo
HEXO
HEXO
$0.71
+2.5%
$0.87
$0.66
$3.84
$31.24M1.35880,508 shs305,500 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$5.03
-0.8%
$5.30
$4.32
$14.45
$700.87M1.181.08 million shs809,884 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
-1.32%-2.74%+11.90%+21.51%+109.13%
The Flowr Co. stock logo
FLWR
Flowr
0.00%0.00%0.00%0.00%0.00%
HEXO Corp. stock logo
HEXO
HEXO
0.00%0.00%0.00%0.00%0.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-0.79%-10.97%-7.37%-18.34%-50.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
2.8076 of 5 stars
0.02.00.80.03.20.03.8
The Flowr Co. stock logo
FLWR
Flowr
N/AN/AN/AN/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.8932 of 5 stars
3.41.00.00.02.53.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
2.63
Moderate BuyN/AN/A
The Flowr Co. stock logo
FLWR
Flowr
0.00
N/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
0.00
N/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.88
Moderate Buy$30.25501.39% Upside

Current Analyst Ratings Breakdown

Latest FLWR, DB, HEXO, and VIR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/28/2025
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/25/2025
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
7/11/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeModerate Buy$12.00
6/10/2025
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/22/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
5/12/2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $14.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
$71.84B0.90$2.97 per share10.94$44.47 per share0.73
The Flowr Co. stock logo
FLWR
Flowr
C$12.92M0.83C$0.00 per share8.33C$0.00 per share-25.00
HEXO Corp. stock logo
HEXO
HEXO
$146.20M0.21N/AN/A$2.44 per share0.29
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$74.21M9.37N/AN/A$8.35 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
$4.70B$2.6312.3710.460.407.67%6.01%0.35%N/A
The Flowr Co. stock logo
FLWR
Flowr
N/A-C$0.21N/AN/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$521.96M-$4.22N/AN/AN/A-2,769.04%-47.46%-39.33%8/6/2025 (Confirmed)

Latest FLWR, DB, HEXO, and VIR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83N/AN/AN/A$2.38 millionN/A
7/24/2025Q2 2025 Pre Recorded
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
$0.78$0.54-$0.24$0.54$7.80 billion$9.21 billion
5/7/2025Q1 2025
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.83-$0.88-$0.05-$0.88$8.59 million$3.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
N/AN/AN/AN/A4 Years
The Flowr Co. stock logo
FLWR
Flowr
N/AN/AN/AN/AN/A
HEXO Corp. stock logo
HEXO
HEXO
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
1.39
0.79
0.79
The Flowr Co. stock logo
FLWR
Flowr
71.27
1.13
0.15
HEXO Corp. stock logo
HEXO
HEXO
0.01
0.41
0.24
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
6.79
6.79

Institutional Ownership

CompanyInstitutional Ownership
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
27.90%
The Flowr Co. stock logo
FLWR
Flowr
N/A
HEXO Corp. stock logo
HEXO
HEXO
7.78%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%

Insider Ownership

CompanyInsider Ownership
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
N/A
The Flowr Co. stock logo
FLWR
Flowr
N/A
HEXO Corp. stock logo
HEXO
HEXO
4.69%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Deutsche Bank Aktiengesellschaft stock logo
DB
Deutsche Bank Aktiengesellschaft
89,7531.99 billionN/AOptionable
The Flowr Co. stock logo
FLWR
Flowr
186426.47 millionN/ANot Optionable
HEXO Corp. stock logo
HEXO
HEXO
1,27744.00 million41.93 millionOptionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
580138.24 million116.12 millionOptionable

Recent News About These Companies

Vir Biotechnology: Hep B And Cancer Projects March On

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Deutsche Bank Aktiengesellschaft stock logo

Deutsche Bank Aktiengesellschaft NYSE:DB

$32.54 -0.44 (-1.33%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$32.76 +0.22 (+0.66%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Deutsche Bank Aktiengesellschaft, a stock corporation, provides corporate and investment banking, and asset management products and services to private individuals, corporate entities, and institutional clients in Germany, the United Kingdom, rest of Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through Corporate Bank, Investment Bank, Private Bank, and Asset Management segments. The Corporate Bank segment offers cash management, trade finance and lending, trust and agency, and securities services, as well as risk management solutions. The Investment Bank segment provides debt origination, merger and acquisitions, foreign exchange, and equity advisory and origination platform services. The Private Bank segment offers payment and account services, and credit and deposit products, as well as investment advice products, such as environmental, social, and governance products. This segment also provides banking, wealth management, other financial, and postal and parcel services; and supports in planning, managing and investing wealth, financing personal and business interests, and servicing institutional and corporate needs. The Asset Management segment offers investment solutions, such as alternative investments, which include real estate, infrastructure, liquid real assets, and sustainable investments; and various other services, including insurance and pension solutions, asset liability management, portfolio management solutions, and asset allocation advisory to individuals and institutions. Deutsche Bank Aktiengesellschaft was founded in 1870 and is headquartered in Frankfurt am Main, Germany.

Flowr stock logo

Flowr CVE:FLWR

C$0.02 0.00 (0.00%)
As of 10/17/2022

The Flowr Corporation cultivates, produces, and sells cannabis in Canada. The company offers dried flowers and pre-rolls. It also has operations in Canada, Portugal, and the European Union. The company was incorporated in 2016 and is headquartered in Toronto, Canada.

HEXO stock logo

HEXO NYSE:HEXO

HEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.

Vir Biotechnology stock logo

Vir Biotechnology NASDAQ:VIR

$5.03 -0.04 (-0.79%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$5.17 +0.14 (+2.86%)
As of 08/1/2025 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.